相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
X. H. Wu et al.
ANNALS OF ONCOLOGY (2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee et al.
CANCER (2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment
Rachel Campbell et al.
GYNECOLOGIC ONCOLOGY (2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee et al.
CANCER (2021)
Latest clinical evidence of maintenance therapy in ovarian cancer
Christine S. Walsh
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann et al.
LANCET ONCOLOGY (2020)
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi et al.
LANCET ONCOLOGY (2020)
It is not just the drugs that matter: the nocebo effect
Marek Z. Wojtukiewicz et al.
CANCER AND METASTASIS REVIEWS (2019)
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote et al.
GYNECOLOGIC ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander et al.
BRITISH JOURNAL OF CANCER (2018)
Cancer of the ovary, fallopian tube, and peritoneum
Jonathan S. Berek et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting A Systematic Review and Meta-analysis
Matias Rodrigo Chacon et al.
JAMA NETWORK OPEN (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Comparative nocebo effects in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort
Jared C. Foster et al.
CANCER (2017)
The placebo effect in thyroid cancer: a meta-analysis
Maria Llavero-Valero et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer
Filippo Montemurro et al.
JAMA ONCOLOGY (2016)
The nocebo effect of drugs
Sara Planes et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Assessing Bias in Studies of Prognostic Factors
Jill A. Hayden et al.
ANNALS OF INTERNAL MEDICINE (2013)
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2013)
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Paul Sabbatini et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo and Nocebo Effects in Randomized Double-Blind Clinical Trials of Agents for the Therapy for Fatigue in Patients With Advanced Cancer
Maxine de la Cruz et al.
CANCER (2010)
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Jonathan Berek et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinurn containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study
H. Hirte et al.
GYNECOLOGIC ONCOLOGY (2006)
分享论文
